A Phase 3 interventional study of Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in United Kingdom. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Biocon Biologics UK Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.
Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2022, is one of 10 in phase 3, and was the 45th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:
AO Foundation, AO Spine · Sites in United Kingdom, United States, Argentina and 11 more countries
Ages 50+
Promedius Inc · Sites in United Kingdom, Netherlands
Ages 50+ · Healthy volunteers
Bradford Institute for Health Research · Sites in United Kingdom
Ages 70+
King's College London · Sites in United Kingdom
Ages 18+
Relation Therapeutics · Sites in United Kingdom
Ages 18–110
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 55 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 11 · Phase 4 4
First in 1992; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 479 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 110 across the 35 interventional studies, 440 across the 21 observational. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 57 have an industry lead sponsor. The 10 most frequent:
Biocon Biologics UK Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Biocon Biologics UK Ltd has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoporosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07421713Promedius IncA Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older | 2026-11-30 |
| NCT05889598Loughborough UniversityResistance Exercise Training to Improve Bone and Articular Cartilage Health in Women | 2026-12-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Osteoporosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis
The study will consist of 3 study periods: Screening period; Part 1, double-blind active-controlled period; and Part 2, transition period. In the double-blind active-controlled period, eligible Patients will be randomized in a 1:1 ratio to receive either Bmab 1000 or Prolia®. Prior to dosing At Week 52, patients in Prolia® treatment group will be randomized again in a 1:1 ratio to either continue on Prolia® or be transitioned to Bmab 1000. To maintain the study blinding, the patients in the original Bmab 1000 arm will also go through the re-randomization procedure; however, they will continue to receive Bmab 1000. The interventions (Bmab 1000 or Prolia®) will be administered subcutaneously every 6 months. End-of-study visit will be at Week 78 post randomization (Month 18).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For prior or ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements) following points to be considered for the prior to the screening visit:
a. Oral bisphosphonate i. Ineligible if used for 3 or more years cumulatively ii. If used for \<3 years, a gap of at least 1 year since the last dose is required at the screening visit b. Dose received any time
Evidence of any of the following per the patient's history, DXA, or X-ray review and/or current disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Bmab 1000
Biological: Prolia®
60 mg administered as a single SC (subcutaneous) injection once every 6 months.
60 mg administered as a single SC injection once every 6 months
Percentage Change in Lumbar Spine BMD (Bone Mineral Density)
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in lumbar spine BMD
Time frame: Baseline and Week 52
AUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen)
To demonstrate pharmacodynamic equivalence between Bmab 1000 and Prolia® based on AUEC of the bone resorption marker sCTX from baseline to week 26
Time frame: Baseline to Week 26
Percentage Change in Lumbar Spine BMD
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 26 in lumbar spine BMD
Time frame: Baseline and Week 26
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD
Time frame: Baseline upto week 26
Serum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide)
To compare bone turnover between Bmab 1000 and Prolia® based on P1NP after the first dose
Time frame: Baseline up to Week 52
Incidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose
To compare safety and tolerability of 2 administrations of Bmab 1000 and Prolia® 6 months apart
Time frame: Baseline up to Week 78
Incidence of ADA (Anti-drug Antibody)
To compare immunogenicity between Bmab 1000 and Prolia®
Time frame: Week 78 (Transition Period)
Incidence of ADA (Anti-drug Antibody)
To compare immunogenicity between Bmab 1000 and Prolia®
Time frame: Baseline up to Week 52 (Double-blind Active-controlled Period)
Incidence of NAb (Neutralizing Antibody) up to Week 52
To compare immunogenicity between Bmab 1000 and Prolia®
Time frame: Baseline up to Week 52 (Double-blind Active-controlled Period)
Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry)
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD
Time frame: Week 52
Incidence of NAb (Neutralizing Antibody) up to Week 52
To compare immunogenicity between Bmab 1000 and Prolia®
Time frame: Week 78 (Transition Period)
Percentage Change From Baseline in Hip BMD
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Hip BMD
Time frame: Week 78
Percentage Change From Baseline in Femoral BMD
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Femoral BMD
Time frame: Week 78
Minimum Concentration (Cmin) of sCTX
To compare minimum Concentration (Cmin) of sCTX between Bmab 1000 and Prolia®
Time frame: baseline to Week 26
Denosumab Concentrations at Weeks 26
Serum Concentrations of Denosumab
Time frame: Weeks 26
Denosumab Concentrations at Weeks 52
Serum Concentrations of Denosumab
Time frame: Weeks 52
Denosumab Concentrations at Weeks 78
Serum Concentrations of Denosumab
Time frame: Weeks 78
Percentage Change From Baseline in Femoral BMD
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in Femoral BMD
Time frame: Week 52
The study was conducted at 42 sites across 4 countries, and enrolled 479 subjects
| Milestone | Part 1: Bmab 1000; Part 2: Bmab 1000-Bmab 1000 | Part 1: Prolia®; Part 2: Prolia®-Bmab 1000 | Part 1: Not Applicable; Part 2: Prolia®-Prolia® |
|---|---|---|---|
| Started | 238 | 240 | 0 |
| Completed | 218 | 208 | 0 |
| Not completed | 20 | 32 | 0 |
| Milestone | Part 1: Bmab 1000; Part 2: Bmab 1000-Bmab 1000 | Part 1: Prolia®; Part 2: Prolia®-Bmab 1000 | Part 1: Not Applicable; Part 2: Prolia®-Prolia® |
|---|---|---|---|
| Started | 218 | 104 | 104 |
| Completed | 216 | 103 | 103 |
| Not completed | 2 | 1 | 1 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in lumbar spine BMD
| Percent change | Bmab 1000 and Prolia | Prolia® |
|---|---|---|
| Percentage Change in Lumbar Spine BMD (Bone Mineral Density) | 1.698 ± 0.5115 | 1.440 ± 0.5089 |
To demonstrate pharmacodynamic equivalence between Bmab 1000 and Prolia® based on AUEC of the bone resorption marker sCTX from baseline to week 26
| day*pg/mL | Bmab 1000 | Prolia®: |
|---|---|---|
| AUEC (Area Under the Effect Curve) of the Bone Resorption Marker sCTX (Serum C-terminal Telopeptide of Type 1 Collagen) | 127 ± 85.2 | 123 ± 77.3 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 26 in lumbar spine BMD
| Percent change | Bmab 1000 | Prolia®: |
|---|---|---|
| Percentage Change in Lumbar Spine BMD | 3.872 ± 0.7885 | 3.699 ± 0.7860 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD
| Percent change | Bmab 1000 | Prolia®: |
|---|---|---|
| Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry) | 1.698 ± 0.5115 | 1.440 ± 0.5089 |
To compare bone turnover between Bmab 1000 and Prolia® based on P1NP after the first dose
| ng/ml | Bmab 1000 | Prolia®: |
|---|---|---|
| Serum Concentrations of P1NP (Procollagen Type 1 N-terminal Propeptide) | 69.4 ± 161 | 42.9 ± 94 |
To compare safety and tolerability of 2 administrations of Bmab 1000 and Prolia® 6 months apart
| Participants | Bmab 1000-Bmab 1000 | Bmab 1000 -Prolia | Prolia®:-Prolia |
|---|---|---|---|
| Incidence of TEAEs (Treatment-emergent Adverse Events) up to 6 Months After the Second Dose | 55 | 29 | 27 |
To compare immunogenicity between Bmab 1000 and Prolia®
| Participants | Bmab 1000 (Bmab 1000) | Bmab 1000 (Prolia) | Prolia (Prolia) |
|---|---|---|---|
| Incidence of ADA (Anti-drug Antibody) | 46 | 13 | 14 |
To compare immunogenicity between Bmab 1000 and Prolia®
| Participants | Bmab 1000 | Prolia®: |
|---|---|---|
| Incidence of ADA (Anti-drug Antibody) | 215 | 205 |
To compare immunogenicity between Bmab 1000 and Prolia®
| Participants | Bmab 1000 | Prolia®: |
|---|---|---|
| Incidence of NAb (Neutralizing Antibody) up to Week 52 | 7 | 5 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline, at Week 26 and Week 52 in lumbar spine BMD
| Percent change | Bmab 1000 | Prolia®: |
|---|---|---|
| Percentage Change in Total Hip BMD by DXA (Dual-energy X-ray Absorptiometry) | 2.224 ± 0.5532 | 2.132 ± 0.5513 |
To compare immunogenicity between Bmab 1000 and Prolia®
| Participants | Bmab 1000-Bmab 1000 | Bmab 1000 - Prolia | Prolia - Prolia |
|---|---|---|---|
| Incidence of NAb (Neutralizing Antibody) up to Week 52 | 3 | 0 | 0 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Hip BMD
| Percent change | Bmab 1000 - Bmab 1000 | Bmab 1000 - Prolia | Prolia - Prolia |
|---|---|---|---|
| Percentage Change From Baseline in Hip BMD | 4.011 ± 2.7744 | 4.052 ± 3.4300 | 3.483 ± 2.6155 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 78 in Femoral BMD
| Percent change | Bmab 1000- Bmab 1000 | Bmab 1000 - Prolia | Prolia - Prolia |
|---|---|---|---|
| Percentage Change From Baseline in Femoral BMD | 3.666 ± 3.6640 | 3.333 ± 3.5021 | 2.834 ± 3.9551 |
To compare minimum Concentration (Cmin) of sCTX between Bmab 1000 and Prolia®
| pg/mL | Bmab 1000 | Prolia®: |
|---|---|---|
| Minimum Concentration (Cmin) of sCTX | 41.5 ± 18.2 | 41.1 ± 17.8 |
Serum Concentrations of Denosumab
| ng/mL | Bmab 1000 | Prolia®: |
|---|---|---|
| Denosumab Concentrations at Weeks 26 | 53.6 ± 119 | 40.7 ± 88.1 |
Serum Concentrations of Denosumab
| ng/mL | Bmab 1000 | Prolia®: |
|---|---|---|
| Denosumab Concentrations at Weeks 52 | 69.4 ± 161 | 42.9 ± 94.0 |
Serum Concentrations of Denosumab
| ng/mL | Bmab 1000 - Bmab 1000 | Bmab 1000 - Prolia | Prolia - Prolia |
|---|---|---|---|
| Denosumab Concentrations at Weeks 78 | 87.6 ± 223 | 72.1 ± 174 | 66.2 ± 111 |
To demonstrate equivalent efficacy between Bmab 1000 and Prolia® based on percentage change from baseline at Week 52 in Femoral BMD
| Percent change | Bmab 1000 | Prolia®: |
|---|---|---|
| Percentage Change From Baseline in Femoral BMD | 2.138 ± 0.8042 | 1.767 ± 0.7999 |
Collected over 0- 78 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bmab 1000 | 0/342 (0%) | 15/218 (6.9%) | 144/218 (66.1%) |
| Prolia®: | 1/240 (0.4%) | 2/104 (1.9%) | 72/104 (69.2%) |
| Event | Bmab 1000 | Prolia®: |
|---|---|---|
| Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/218 | 1/104 |
| Atrial fibrillationCardiac disorders | 0/218 | 1/104 |
| DizzinessNervous system disorders | 2/218 | 0/104 |
| Abdominal painGastrointestinal disorders | 1/218 | 0/104 |
| Gastric ulcerGastrointestinal disorders | 1/218 | 0/104 |
| Inflammatory bowel diseaseGastrointestinal disorders | 1/218 | 0/104 |
| UrosepsisInfections and infestations | 1/218 | 0/104 |
| Vestibular neuronitisInfections and infestations | 1/218 | 0/104 |
| Musculoskeletal disorderMusculoskeletal and connective tissue disorders | 1/218 | 0/104 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/218 | 0/104 |
| Event | Bmab 1000 | Prolia®: |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 18/218 | 12/104 |
| NasopharyngitisInfections and infestations | 13/218 | 8/104 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 7/218 | 8/104 |
| COVID-19Infections and infestations | 10/218 | 7/104 |
| Urinary tract infectionInfections and infestations | 14/218 | 2/104 |
| SinusitisInfections and infestations | 0/218 | 6/104 |
| Back painMusculoskeletal and connective tissue disorders | 12/218 | 3/104 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 11/218 | 1/104 |
| HeadacheNervous system disorders | 11/218 | 5/104 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 10/218 | 5/104 |
| Age, Categorical(Participants) | Bmab 1000 | Prolia®: | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 84 | 88 | 172 |
| >=65 years | 154 | 153 | 307 |
| Age, Continuous(years) | Bmab 1000 | Prolia®: | Total |
|---|---|---|---|
| Mean | 66.7 ± 5.55 | 66.5 ± 5.77 | 66.6 ± 5.66 |
| Sex: Female, Male(Participants) | Bmab 1000 | Prolia®: | Total |
|---|---|---|---|
| Female | 238 | 241 | 479 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Bmab 1000 | Prolia®: | Total |
|---|---|---|---|
| White | 237 | 241 | 478 |
| Japanese | 1 | 0 | 1 |
| Region of Enrollment(participants) | Bmab 1000 | Prolia®: | Total |
|---|---|---|---|
| United Kingdom | 3 | 3 | 6 |
| Europe | 235 | 238 | 473 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Jun 2024, 24 months.
Results were first posted in Aug 2025, 1 year 2 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 24 months is close to that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biocon Biologics UK Ltd